Searched for: in-biosketch:true
person:carucj01
MAGE-A3 is a prognostic biomarker for poor clinical outcome in cutaneous squamous cell carcinoma with perineural invasion via modulation of cell proliferation
Chen, Aaron; Santana, Alexis L; Doudican, Nicole; Roudiani, Nazanin; Laursen, Kristian; Therrien, Jean-Philippe; Lee, James; Felsen, Diane; Carucci, John A
Perineural invasion is a pathologic process of neoplastic dissemination along and invading into the nerves. Perineural invasion is associated with aggressive disease and a greater likelihood of poor outcomes. In this study, 3 of 9 patients with cutaneous squamous cell carcinoma and perineural invasion exhibited poor clinical outcomes. Tumors from these patients expressed high levels of MAGE-A3, a cancer testis antigen that may contribute to key processes of tumor development. In addition to perineural invasion, the tumors exhibited poor differentiation and deep invasion and were subsequently classified as Brigham and Women's Hospital tumor stage 3. Cyclin E, A and B mRNA levels were increased in these tumors compared with normal skin tissues (102.93±15.03 vs. 27.15±4.59, 36.83±19.41 vs. 11.59±5.83, 343.77±86.49 vs. 95.65±29.25, respectively; p<0.05). A431 cutaneous squamous cell carcinoma cells pretreated with MAGE-A3 antibody exhibited a decreased percentage S-phase cells (14.13±2.8% vs. 33.97±1.1%; p<0.05) and reduced closure in scratch assays (43.88±5.49% vs. 61.17±3.97%; p = 0.0058). In a syngeneic animal model of squamous cell carcinoma, immunoblots revealed overexpression of MAGE-A3 and cyclin E, A, and B protein in tumors at 6 weeks. However, knockout of MAGE-A3 expression caused a reduction in tumor growth (mean tumor volume 155.3 mm3 vs. 3.2 mm3) compared with parental cells. These results suggest that MAGE-A3 is a key mediator in cancer progression. Moreover, elevated collagen XI and matrix metalloproteases 3, 10, 11, and 13 mRNA levels were observed in poorly differentiated cutaneous squamous cell carcinoma with perineural invasion compared with normal skin tissue (1132.56±882.7 vs. 107.62±183.62, 1118.15±1109.49 vs. 9.5±5, 2603.87±2385.26 vs. 5.29±3, 957.95±627.14 vs. 400.42±967.66, 1149.13±832.18 vs. 19.41±35.62, respectively; p<0.05). In summary, this study highlights the potential prognostic value of MAGE-A3 in clinical outcomes of cutaneous squamous cell carcinoma patients.
PMID: 33227008
ISSN: 1932-6203
CID: 4680332
Scalp nodule in a 59-year-old female What is your diagnosis? [Editorial]
Wilken, Reason; Carucci, John A.; Brinster, Nooshin K.; Stevenson, Mary L.
ISI:000546107300001
ISSN: 0011-9059
CID: 4526612
Decreased cytotoxic T cells and TCR clonality in organ transplant recipients with squamous cell carcinoma
Frazzette, Nicholas; Khodadadi-Jamayran, Alireza; Doudican, Nicole; Santana, Alexis; Felsen, Diane; Pavlick, Anna C; Tsirigos, Aristotelis; Carucci, John A
T-cell landscape differences between cutaneous squamous cell carcinoma (cSCC) tumors in immune competent (SCC in IC) and immunocompromised organ transplant recipients (TSCC in OTR) are unclear. We developed an analytical method to define tumor infiltrating lymphocyte (TIL) phenotype in cSCC from immune competent and immune suppressed patients using single-cell TCR sequencing and gene expression data. TSCC exhibits reduced proportions of cytotoxic and naïve TILs and similar numbers of regulatory TILs. Fewer, more heterogeneous TCR clonotypes are observed in TIL from OTR. Most TCR sequences for top ten clonotypes correspond to known antigens, while 24% correspond to putative neoantigens. OTR show increased cSCC events over 12 months possibly due to reduced cytotoxic T-cells. Our novel method of barcoding CD8+ T-cells is the first providing gene expression and TCR sequences in cSCC. Knowledge regarding putative antigens recognized by TCRs with phenotypic function of T-cells bearing those TCRs could facilitate personalized cSCC treatments.
PMCID:7270180
PMID: 32550269
ISSN: 2397-768x
CID: 4484902
Single-center retrospective review of the use of checkpoint inhibitors in merkel cell carcinoma patients [Meeting Abstract]
Babadzhanov, M.; Doudican, N.; Ovits, C.; Canavan, T.; Stevenson, M.; Pavlick, A.; Carucci, J.
ISI:000554564400420
ISSN: 0022-202x
CID: 4562172
Initial Skin Cancer Screening for Solid Organ Transplant Recipients in the United States: Delphi Method Development of Expert Consensus Guidelines
Crow, Lauren D; Jambusaria-Pahlajani, Anokhi; Chung, Christina L; Baran, David A; Lowenstein, Stefan E; Abdelmalek, Mark; Ahmed, Rehana L; Anadkat, Milan J; Arcasoy, Selim M; Berg, Daniel; Bibee, Kristin P; Billingsley, Elizabeth; Black, William H; Blalock, Travis W; Bleicher, Melissa; Brennan, Daniel C; Brodland, David G; Brown, Mariah R; Carroll, Bryan T; Carucci, John A; Chang, Timothy W; Chaux, George; Cusack, Carrie Ann; Dilling, Daniel F; Doyle, Alden; Emtiazjoo, Amir M; Ferguson, Nkanyezi H; Fosko, Scott W; Fox, Matthew C; Goral, Simin; Gray, Alice L; Griffin, John R; Hachem, Ramsey R; Hall, Shelley A; Hanlon, Allison M; Hayes, Don; Hickey, Gavin W; Holtz, Jonathan; Hopkins, R Samuel; Hu, Jenny; Huang, Conway C; Jiang, Shang I Brian; Kapnadak, Siddhartha G; Kraus, Edward S; Lease, Erika D; Leca, Nicolae; Lee, James C; Leitenberger, Justin J; Lim, Mary Ann; Longo, Maria I; Malik, Shahid M; Mallea, Jorge M; Menter, Alan; Myers, Sarah A; Neuburg, Marcy; Nijhawan, Rajiv I; Norman, Douglas J; Otley, Clark C; Paek, So Yeon; Parulekar, Amit D; Patel, Manisha J; Patel, Vishal Anil; Patton, Timothy J; Pugliano-Mauro, Melissa; Ranganna, Karthik; Ravichandran, Ashwin K; Redenius, Rachel; Roll, Garrett R; Samie, Faramarz H; Shin, Thuzar; Singer, Jonathan P; Singh, Pooja; Soon, Seaver L; Soriano, Teresa; Squires, Ronald; Stasko, Thomas; Stein, Jennifer A; Taler, Sandra J; Terrault, Norah A; Thomas, Christie P; Tokman, Sofya; Tomic, Rade; Twigg, Amanda R; Wigger, Mark A; Zeitouni, Nathalie C; Arron, Sarah T
BACKGROUND:Skin cancer is the most common malignancy affecting solid organ transplant recipients (SOTR), and SOTR experience an increased skin cancer-associated in morbidity and mortality. There are no formal multidisciplinary guidelines for skin cancer screening after transplant, and current practices are widely variable. METHODS:We conducted three rounds of Delphi-method surveys with a panel of 84 U.S. dermatologists and transplant physicians to establish skin cancer screening recommendations for SOTR. RESULTS:The transplant team should risk stratify SOTR for screening, and dermatologists should perform skin cancer screening by full body skin examination. SOTR with a history of skin cancer should continue regular follow-up with dermatology for skin cancer surveillance post-transplant. High-risk patients include thoracic organ recipients, SOTR age 50 and above, and male SOTR. High-risk Caucasian patients should be screened within 2 years after transplant, all Caucasian, Asian, Hispanic, and high-risk African American patients should be screened within 5 years after transplant. No consensus was reached regarding screening for low-risk African American SOTR. CONCLUSION/CONCLUSIONS:We propose a standardized approach to skin cancer screening in SOTR based on multi-disciplinary expert consensus. These guidelines prioritize and emphasize the need for screening for SOTR at greatest risk for skin cancer.
PMID: 31502728
ISSN: 1432-2277
CID: 4087802
Skin Cancer in Transplant Recipients: Scientific Retreat of The International Immunosuppression and Transplant Skin Cancer Collaborative and Skin Care in Organ Transplant Patients-Europe
Stevenson, Mary L; Carucci, John; Colegio, Oscar R
The International Immunosuppression and Transplant Skin Cancer Collaborative (ITSCC) is an organization of more than 500 physicians and scientists focused on the treatment of cutaneous malignancies following solid organ transplantation and in other forms of immunosuppression. It is well known that solid organ transplant recipients (SOTRs) have an approximate 100-fold increase in the risk of developing skin cancer with consensus guidelines recommending these patients be managed as high risk for local recurrence and metastasis associated with poor outcomes. In September 2018, ITSCC and its European counterpart, the Skin Care in Organ Transplant Patients-Europe (SCOPE), held their biennial scientific retreat in Essex, MA to discuss novel findings in the pathogenesis of cutaneous malignancy including new treatment and prevention strategies in this at risk population for significant morbidity and mortality from their cutaneous disease. This meeting report is a summary of the novel findings discussed.
PMID: 31628869
ISSN: 1399-0012
CID: 4140842
Evidence-Based Clinical Practice Guidelines for Management of Microcystic Adnexal Carcinoma
Carucci, John A; Canavan, Theresa N
PMID: 31268489
ISSN: 2168-6084
CID: 3968122
Stratification of Poor Outcomes for Cutaneous Squamous Cell Carcinoma in Immunosuppressed Patients Using the American Joint Committee on Cancer Eighth Edition and Brigham and Women's Hospital Staging Systems
Blechman, Adam B; Carucci, John A; Stevenson, Mary L
BACKGROUND:Staging systems for cutaneous squamous cell carcinoma (CSCC) include Brigham and Women's Hospital (BWH) and American Joint Committee on Cancer staging system, eighth edition (AJCC-8). OBJECTIVE:To evaluate and compare AJCC-8 and BWH staging systems for CSCC in immunosuppressed patients. MATERIALS AND METHODS/METHODS:A retrospective cohort study of immunosuppressed patients diagnosed with primary CSCC from 2012 to 2016. The main end point was any poor outcome (PO), which included local recurrence, nodal metastasis, and disease-specific death. RESULTS:Fifty-eight immunosuppressed patients had 263 CSCCs. Fifty percent of tumors were AJCC-8 T1, 44.7% T2, and 4.8% T3. Fifty percent of tumors were BWH T1, 48.5% T2a, 1.3% T2b, and 0.4% T3. Risk of PO for AJCC-8 was 1.7%, 8.8%, and 36.4% for T1, T2, and T3, respectively (p < .01). Risk of PO for BWH was 1.8%, 9.9%, 33.3%, and 100.0% for T1, T2a, T2b, and T3, respectively (p < .01). Thirty-six percent of AJCC-8 T3/T4 tumors had POs compared with 5.1% in low T1/T2 stages (p = .002). Fifty percent of BWH T2b/T3 tumors had POs compared with 5.3% in low T1/T2a stages (p = .01). CONCLUSION/CONCLUSIONS:AJCC-8 and BWH staging systems stratify CSCC with similar distinctiveness, homogeneity, and monotonicity for immunosuppressed patients.
PMID: 30640779
ISSN: 1524-4725
CID: 3595182
Expertise in Head and Neck Cutaneous Reconstructive Surgery
Deng, Min; Higgins, H William; Lesiak, Kendra; Decker, Ashley B; Regula, Christie G; Stevenson, Mary L; Raphael, Brian; Depry, Jennifer; Scott, Jeffrey F; Bangash, Haider; Ochoa, Shari A; Ibrahimi, Omar A; Shafai, Aria; Bordeaux, Jeremy S; Carucci, John A; Cook, Jonathan L; Goldman, Glenn D; Rohrer, Thomas E; Lawrence, Naomi
BACKGROUND:The management of skin cancers has evolved with the development of Mohs micrographic surgery and a greater emphasis on surgical training within dermatology. It is unclear whether these changes have translated into innovations and contributions to the reconstructive literature. OBJECTIVE:To assess contributions from each medical specialty to the cutaneous head and neck oncologic reconstructive literature. METHODS:The authors conducted a systematic review of the head and neck reconstructive literature from 2000 through 2015 based on a priori search terms relating to suture technique, linear closure, advancement, rotation, transposition and interpolation flaps, and identified the specialty of the senior authors. RESULTS:The authors identified 74,871 articles, of which 1,319 were relevant. Under suture technique articles, the senior authors were primarily dermatologists (58.2%) and plastic surgeons (20.3%). Under linear closure, the authors were dermatologists (48.1%), plastic surgeons (22.2%), and otolaryngologists (20.4%). Under advancement and rotation flaps, the senior authors were plastic surgeons (40.5%, 38.9%), dermatologists (38.1%, 34.2%), and otolaryngologists (14.4%, 21.6%). Under transposition and interpolation flaps, the senior authors were plastic surgeons (47.3%, 39.4%), dermatologists (32.3%, 27.0%), and otolaryngologists (15.3%, 23.4%). CONCLUSION/CONCLUSIONS:The primary specialties contributing to the cutaneous head and neck reconstructive literature are plastic surgery, dermatology, and otolaryngology.
PMID: 30829776
ISSN: 1524-4725
CID: 3722632
135 Defining the T cell landscape and neoantigens via T-cell receptor sequencing and gene expression profiling in cutaneous squamous cell carcinoma [Meeting Abstract]
Doudican, N A; Santana, A; Felsen, D; Khodadadi-Jamayran, A; Tsirigos, A; Carucci, J
Background: Immune response is key in defense against cutaneous squamous cell carcinoma (cSCC). We aim to better target T cell killing to treat cancer. Method(s): CD8+ tumor infiltrating lymphocytes (TILs) obtained from fresh SCC tumor specimens from immunocompetent (n=5) versus organ transplant recipients (OTRs; n=6) were subject to single-cell RNA profiling and T-cell receptor (TCR) sequencing. Data were analyzed using scSeqR. Result(s): CD8+ TILs were clustered based on gene expression as follows: effector T cells (GZMA, GZMB, IFN-gamma); naive T cells (CCR7, LEF1, TCF7, IL7R); exhausted T cells (BTLA, CTLA4, PDCD1, TIM3, LAG3); and regulatory T cells (FOXP3, STAT3, TNFSRF). CD8+ TIL clonotypes show potential for response to known and uncharacterized antigens. CD8+ TILs from OTRs exhibited more homogeneous gene expression compared with immunocompetent patients. Regulatory and exhausted T cells were reduced in OTRs. TILs from both OTRs and immunocompetent patients showed clonality. However, more TCR clonotypes were observed in immunocompetent patients (mean = 1140) than OTRs (mean = 544). We analyzed common beta TCR from SCC via multiple bioinformatics-based approaches. Clonotypes common to more than one SCC from immune competent patients included breast cancer-associated keratin 19 and proliferation-associated striatin. OTR clonotypes included tumor-suppressor associated MOB kinase 1A and breast cancer-associated ADAM9. Conclusion(s): CD8+ TILs from cSCC showed clonotype restriction, implying T cell mediated anti-tumor response. We will refine our understanding of the SCC T cell landscape and identify and screen neoantigens with the goal of developing rational T cell-based cancer therapy.
EMBASE:2001808802
ISSN: 1523-1747
CID: 3811712